- Home
- DOCU vs QGEN Comparison
DOCU vs QGEN Comparison
Compare DOCU & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOCU | QGEN |
|---|---|---|
| Founded | 2003 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 10.2B |
| IPO Year | 2018 | 1998 |
Fundamental Metrics
Financial Performance| Metric | DOCU | QGEN |
|---|---|---|
| Price | $47.60 | $41.02 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 17 | 8 |
| Target Price | ★ $63.33 | $50.26 |
| AVG Volume (30 Days) | ★ 4.3M | 1.3M |
| Earning Date | 06-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 5.84% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.48 | N/A |
| Revenue | ★ $3,219,500,000.00 | N/A |
| Revenue This Year | $10.58 | $8.18 |
| Revenue Next Year | $7.33 | $5.71 |
| P/E Ratio | $30.88 | ★ $24.01 |
| Revenue Growth | ★ 8.16 | N/A |
| 52 Week Low | $40.16 | $38.80 |
| 52 Week High | $94.67 | $57.82 |
Technical Indicators
Market Signals| Indicator | DOCU | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 53.10 | 44.85 |
| Support Level | $45.03 | $38.80 |
| Resistance Level | $50.42 | $48.53 |
| Average True Range (ATR) | 2.39 | 0.79 |
| MACD | 0.12 | 0.34 |
| Stochastic Oscillator | 75.18 | 53.32 |
Price Performance
Historical ComparisonAbout DOCU DocuSign Inc.
Docusign offers Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its initial public offering in 2018.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).